rel="nofollow" href="#ulink_8fa13477-c25f-52f2-949f-9a801e4517fe">Table 3.4 Properties of the core variation compounds 16–20, 2.Table 3.5 In vivo pharmacokinetic properties of 17, 20, vericiguat 2 in com...Table 3.6 Nonclinical pharmacodynamics of vericiguat in vitro, ex vivo and Table 3.7 Population pharmacokinetic model based steady‐state geometric mea...
2 Chapter 4Table 4.1 Profiles of compounds 14a, 14b, 15a, and 15b. Table 4.2 PK profile of SCH 900229.Table 4.3 In vitro profiles of 27 and 32 in comparison with 18 (E‐2012).Table 4.4 PK parameters of compounds 27 and 32 in rat, dog, and monkey a .Table 4.5 In vivo PK/PD profile of 27 and 32 in rat.
3 Chapter 5Table 5.1 Discovery of C6 morpholine carboxylic acid 4‐H HAP analogues.Table 5.2 Physicochemical and ADME properties of compound 3.Table 5.3 Selected pharmacokinetics parameters of compound 3 in male ICR mi...Table 5.4 Effects on HBsAg reduction of analogues 19–35.Table 5.5 Further SAR at the C9 and C10 positions: effects on HBsAg reducti...Table 5.6 Further SAR at the C6 position: effects on HBsAg reduction and ph...Table 5.7 Rat SDPK profiles of selected BAQ compounds a .Table 5.8 Effect of Ziresovir on the wild type and mutant strains a .
4 Chapter 6Table 6.1 Binding affinities and functional agonist or antagonist responses...Table 6.2 Residues interacting with L‐Glu in the orthosteric site.Table 6.3 Mean plasma pharmacokinetic parameters for 11 following single i....Table 6.4 Mean plasma and cerebrospinal fluid concentrations of 11 followin...Table 6.5 Mean plasma pharmacokinetic parameters of 19 following single i.v...Table 6.6 Mean plasma and cerebrospinal fluid concentrations of 19 at 1 h f...Table 6.7 FLIPR agonist responses produced by 11 in AV12 cells transiently ...Table 6.8 Summary of plasma pharmacokinetic parameters of 11 after single d...Table 6.9 Summary of plasma and cerebrospinal fluid pharmacokinetic paramet...Table 6.10 Primary statistical analysis of BOLD response to ketamine challe...
5 Chapter 7Table 7.1 In vitro and in vivo parameters for taselisib and GastroPlus expe...
6 Chapter 8Table 8.1 Off‐DNA hit confirmation.Table 8.2 SAR at cycle 4.Table 8.3 SAR at cycle 3.Table 8.4 SAR at cycle 2.Table 8.5 P450 inhibition summary.Table 8.6 Rat PK data summary for selected compounds.
7 Chapter 9Table 9.1 Number of unique GPCR complexes.
8 Chapter 10Table 10.1 SAR on core substitution.Table 10.2 Variation of R2 with fixed R3 and R6.Table 10.3 BPND of [11C]17, [11C]21 and [11C]22 compared with [11C]10. Table 10.4 Key parameters for tracer candidates.Table 10.5 Examples of fluorine‐containing PET tracer candidates.Table 10.6 P‐gp ratios in human, monkey, and rat at 1 and 0.1 μM.Table 10.7 Bmax and Kd values for [3H]10 in rhesus monkey and human striatu...Table 10.8 Test–retest variability for [11C]10 in rhesus monkey a .
9 Chapter 11Table 11.1 Comparison of PROTACs with other therapeutics.Table 11.2 Examples of PROTACs.Table 11.3 Pharmacokinetic data for exemplary PROTACs.Table 11.4 Phase I PK data for ARV‐110.Table 11.5 Preclinical efficacious exposure range of ARV‐110 in mouse.Table 11.6 Preclinical efficacious exposure range of ARV‐471 in mouse.Table 11.7 Phase I PK data for ARV‐471.
10 Chapter 12Table 12.1 Some FDA approved peptide drugs (2005–2019) exemplifying their th...Table 12.2 Some computational, biophysical and biological screening tools u...
11 Chapter 13Table 13.1 ADCs with SG‐3199 (payload) in clinical trials.Table 13.2 ADCs with SG‐1882 (payload) in clinical trials.Table 13.3 ADCs with IGN‐based payloads in clinical trials.Table 13.4 Twelve FDA approved ADCs.
12 Chapter 14Table 14.1 Preclinical PK profiles of olaparib in rat and dog.Table 14.2 Pharmacokinetic parameters of bevacizumab with intravenous dosing...Table 14.3 Pharmacokinetic profiles of olaparib dosed twice daily (b.i.d.) i...Table 14.4 Summary of clinical outcome of PORLA‐1 phase 3 clinical trial [11...Table 14.5 The most common adverse events and the incidence of associated gr...Table 14.6 in vitro activity of ceftazidime–avibactam against selected Gram‐...Table 14.7 Summary of in vivo study results of the ceftazidime and vibactam ...Table 14.8 Single rising dose PK profiles of ceftazidime and avibactam alone...Table 14.9 Single and multiple dose PK profiles of ceftazidime (2000 mg) in ...Table 14.10 Clinical response of ceftazidime and avibactam combination for c...Table 14.11 Clinical response of ceftazidime and avibactam combination plus ...Table 14.12 Percentages of phase 2 ceftazidime/avibactam treatment‐emergent ...Table 14.13 Dosage recommendations for the ceftazidime and avibactam combina...Table 14.14 Primary and secondary efficacy endpoints in mMITT population.Table 14.15 Safety data in safety population up to late follow‐up.Table 14.16 Clinical response in the REPRISE trial a in mMITT population at t...Table 14.17 Clinical cure rate in the RECLAIM 1 and 2 clinical trials.Table 14.18 Clinical cure rate of ceftazidime–avibactam plus metronidazole c...Table 14.19 Clinical cure rate of ceftazidime–avibactam compared with merope...Table 14.20 Per‐pathogen clinical cure rates and per‐patient microbiological...
13 Chapter 15Table 15.1 BinaxNOWTM COVID‐19 Ag Card performance within seven days of symp...Table 15.2 in vitro antiviral activity of remdesivir.Table 15.3 Overall outcome of phase 3 trial carried out by NIAID (NCT0428070...Table 15.4 Key efficacy and safety results from the SIMPLE1 study.Table 15.5 Difference versus placebo of the meantime‐weighted‐average change...Table 15.6 Difference versus placebo of the viral load reduction through day...Table 15.7 Impact of dexamethasone on mortality of hospitalized patients wit...
List of Illustrations
1 Chapter 2Figure 2.1 (a) An overlay of ND‐022 with the natural product soraphen and (b...Figure 2.2 Structures of ND‐022 and ND‐630.Figure 2.3 Superimposed crystal structures of TYK2, JAK1, JAK2, and JAK3 coc...Figure 2.4 (a) Inhibitors known to bind to the switch‐II pocket of KRASG12C....Figure 2.5 Correlation of experimental and calculated binding activity (∂G) ...Figure 2.6 Structures of initial hit and lead compound [130].
2 Chapter 3Figure 3.1 sGC stimulator vericiguat.Figure 3.2 The NO/sGC signaling and natriuretic peptide/pGC signaling with m...Figure 3.3 Recurrent acute events contribute to heart failure progression. W...Figure 3.4 sGC stimulator riociguat.Scheme 3.1 Early days synthesis of vericiguat 2.Scheme 3.2 High yielding route to trisamine 24.